Summary:
Multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg and 90 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.
Qualified Participants Must:
• Be 50-85
• Probable Alzheimer's Disease
• Availability of a study partner.
Qualified Participants May Receive:
May be compensated for time and travel.